Dosing Information for EYLEA® (aflibercept) Injection

Start With EYLEA. Stay With EYLEA.

EYLEA offers flexible dosing options for certain approved indications in a single 2 mg (0.05 mL) formulation.¹

Around 9.0 million doses since launch. Around 790,000 eyes treated with EYLEA since launch.

EYLEA First-Line Offers Flexibility Across Patient Types and Dosing Options Across Several Indications¹

EYLEA 2 mg (0.05 mL) Dosing Schedule¹

Eylea dosing for Wet AMD: Initial dosing 2 mg every 4 weeks x 3 injections. Follow-up dosing options 2 mg every 8 weeks or 2 mg every 4 weeks. After one year of effective therapy 2 mg every 12 weeks.

Although EYLEA may be dosed as frequently as 2 mg every 4 weeks (≈ every 28 days, monthly), additional efficacy was not demonstrated in most patients when EYLEA was dosed every 4 weeks compared to every 8 weeks. Some patients may need every-4-week (monthly) dosing after the first 12 weeks (3 months). Although not as effective as the recommended every-8-week dosing regimen, patients may also be treated with one dose every 12 weeks after one year of effective therapy. Patients should be assessed regularly.

Eylea dosing for Diabetic Macular Edema DME: Initial dosing 2 mg every 4 weeks x 5 injections. Follow-up dosing options 2 mg every 8 weeks or 2 mg every 4 weeks.

Although EYLEA may be dosed as frequently as 2 mg every 4 weeks (≈ every 25 days, monthly), additional efficacy was not demonstrated in most patients when EYLEA was dosed every 4 weeks compared to every 8 weeks. Some patients may need every-4-week (monthly) dosing after the first 20 weeks (5 months).

Eylea dosing for Diabetic Retinopathy DR: Initial dosing 2 mg every 4 weeks x 5 injections. Follow-up dosing 2 mg every 8 weeks or 2mg every 4 weeks.

Eylea dosing for MEfRVO: 2 mg every 4 weeks.

View the safety profile for all indications

Reimbursement Support

Get help navigating the
reimbursement process. Find enrollment forms, sample appeal letters, and more.

See the details

Dosing with EYLEA

EYLEA offers flexible dosing options
for certain approved indications in a single 2mg formulation.

Find out more

News

Keep up to date on
current EYLEA clinical information,
events, and more.

Read the latest

See More Important Safety Information and Indications

EYLEA^® (aflibercept) Injection is contraindicated in patients with ocular or periocular infections, active intraocular inflammation, or known hypersensitivity to aflibercept or to any of the excipients in EYLEA.

Important Safety Information

EYLEA® (aflibercept) Injection is contraindicated in patients with ocular or periocular infections, active intraocular inflammation, or known hypersensitivity to aflibercept or to any of the excipients in EYLEA.
Intravitreal injections, including those with EYLEA, have been associated with endophthalmitis and retinal detachments. Proper aseptic injection technique must always be used when administering EYLEA. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately. Intraocular inflammation has been reported with the use of EYLEA.
Acute increases in intraocular pressure have been seen within 60 minutes of intravitreal injection, including with EYLEA. Sustained increases in intraocular pressure have also been reported after repeated intravitreal dosing with VEGF inhibitors. Intraocular pressure and the perfusion of the optic nerve head should be monitored and managed appropriately.
There is a potential risk of arterial thromboembolic events (ATEs) following intravitreal use of VEGF inhibitors, including EYLEA. ATEs are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause). The incidence of reported thromboembolic events in wet AMD studies during the first year was 1.8% (32 out of 1824) in the combined group of patients treated with EYLEA compared with 1.5% (9 out of 595) in patients treated with ranibizumab; through 96 weeks, the incidence was 3.3% (60 out of 1824) in the EYLEA group compared with 3.2% (19 out of 595) in the ranibizumab group. The incidence in the DME studies from baseline to week 52 was 3.3% (19 out of 578) in the combined group of patients treated with EYLEA compared with 2.8% (8 out of 287) in the control group; from baseline to week 100, the incidence was 6.4% (37 out of 578) in the combined group of patients treated with EYLEA compared with 4.2% (12 out of 287) in the control group. There were no reported thromboembolic events in the patients treated with EYLEA in the first six months of the RVO studies.
Serious adverse reactions related to the injection procedure have occurred in <0.1% of intravitreal injections with EYLEA including endophthalmitis and retinal detachment.
The most common adverse reactions (≥5%) reported in patients receiving EYLEA were conjunctival hemorrhage, eye pain, cataract, vitreous detachment, vitreous floaters, and intraocular pressure increased.

INDICATIONS

EYLEA® (aflibercept) Injection 2 mg (0.05 mL) is indicated for the treatment of patients with Neovascular (Wet) Age-related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR).

Please see the full Prescribing Information for EYLEA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

The information provided in this site is intended only for healthcare professionals in the United States. The products discussed herein may have different product labeling in different countries.

References

EYLEA® (aflibercept) Injection full U.S. Prescribing Information. Regeneron Pharmaceuticals, Inc. May 2019.
Data on file. Regeneron Pharmaceuticals, Inc.

EYLEA and EYLEA4U are registered trademarks of Regeneron Pharmaceuticals, Inc.

05/2019
US-LEA-14070a(1)

Dosing with EYLEA

Start With EYLEA. Stay With EYLEA.

EYLEA First-Line Offers Flexibility Across Patient Types and Dosing Options Across Several Indications1

EYLEA 2 mg (0.05 mL) Dosing Schedule1

References

EYLEA First-Line Offers Flexibility Across Patient Types and Dosing Options Across Several Indications¹

EYLEA 2 mg (0.05 mL) Dosing Schedule¹